html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

go to main content

Listen

- Pagina niet beschikbaar in Nederlands ( NL )
- Seite nicht verfügbar auf Deutsch ( DE )

Go to Radboudumc Radboudumc

Research group Cancer pharmacology

Welcome to Research

I am looking for ...

information on how Radboudumc conducts research →
opportunities for my career within Radboudumc research →
opportunities to participate or invest in Radboudumc research →

Research Research groups Cancer pharmacology

About

We focus on describing, explaining, understanding and modifying the pharmacokinetics of oral anticancer drugs.

Research group leader

prof. dr. Nielka van Erp

Aims

See our most important goals.

read more

Aims

We aim to center our research around the following three topics:

Preclinical cancer pharmacology
Clinical cancer pharmacology
Dose individualization

Publications

See some of our most important scientific articles.

read more

Publications

See the publication list on Web of Science.

Profile page

See the group leader's profile.

see page

Research programs

Programs that are connected to this research group.

Employees
mijnRadboud